Index -
P/E -
EPS (ttm) -3.19
Insider Own 1.93%
Shs Outstand 5.70M
Perf Week -14.89%
Market Cap 11.40M
Forward P/E -
EPS next Y -2.30
Insider Trans 72.45%
Shs Float 5.59M
Perf Month -13.79%
Income -11.77M
PEG -
EPS next Q -0.53
Inst Own 11.74%
Short Float 3.06%
Perf Quarter 15.61%
Sales 6.08M
P/S 1.88
EPS this Y 50.86%
Inst Trans -4.92%
Short Ratio 2.34
Perf Half Y -7.41%
Book/sh -1.13
P/B -
EPS next Y -10.56%
ROA -110.75%
Short Interest 0.17M
Perf Year -33.77%
Cash/sh 0.56
P/C 3.54
EPS next 5Y -
ROE -522.50%
52W Range 0.97 - 3.45
Perf YTD 14.28%
Dividend Est. -
P/FCF -
EPS past 5Y 68.20%
ROI -
52W High -41.95%
Beta 0.58
Dividend TTM -
Quick Ratio 0.41
Sales past 5Y 406.45%
Gross Margin 87.77%
52W Low 106.31%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 0.41
EPS Y/Y TTM 71.07%
Oper. Margin -195.59%
RSI (14) 41.82
Volatility 9.34% 8.06%
Employees 20
Debt/Eq -
Sales Y/Y TTM 733.42%
Profit Margin -193.49%
Recom 1.00
Target Price 19.00
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 63.56%
Payout -
Rel Volume 0.85
Prev Close 2.13
Sales Surprise -1.35%
EPS Surprise 31.19%
Sales Q/Q 231.42%
Earnings May 15 AMC
Avg Volume 73.34K
Price 2.00
SMA20 -10.55%
SMA50 -0.85%
SMA200 9.27%
Trades
Volume 62,563
Change -6.10%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-21 Initiated
Ladenburg Thalmann
Buy
$8
Oct-16-20 Initiated
Maxim Group
Buy
$6
Jun-07-24 07:30AM
May-17-24 05:00PM
May-16-24 03:05AM
May-15-24 08:53PM
04:15PM
07:30AM
Loading…
May-13-24 07:30AM
May-09-24 11:29AM
May-08-24 05:35PM
May-06-24 07:30AM
Apr-22-24 09:00AM
07:00AM
Apr-09-24 07:00AM
Mar-27-24 08:00AM
Mar-25-24 08:00AM
Mar-11-24 07:00AM
08:59AM
Loading…
Mar-07-24 08:59AM
Mar-06-24 01:43PM
(Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM
05:35PM
04:05PM
Feb-27-24 08:00AM
Dec-18-23 07:00AM
Dec-12-23 08:00AM
Nov-29-23 08:00AM
Nov-20-23 07:00AM
Nov-15-23 07:00AM
Nov-13-23 09:31AM
Nov-03-23 07:00AM
Nov-01-23 09:29AM
Oct-31-23 04:10PM
04:05PM
Loading…
04:05PM
Oct-25-23 09:21AM
Oct-23-23 04:05PM
Oct-10-23 07:00AM
Oct-09-23 07:00AM
Sep-19-23 01:07PM
Sep-15-23 11:17AM
Sep-11-23 12:44PM
07:00AM
Sep-08-23 12:49PM
11:18AM
08:30AM
07:00AM
Sep-05-23 01:13PM
07:00AM
Aug-30-23 07:00AM
Aug-18-23 09:55AM
Aug-15-23 10:58AM
(Thomson Reuters StreetEvents)
Aug-14-23 04:05PM
Aug-11-23 06:28PM
08:00AM
06:30AM
Aug-08-23 04:05PM
11:22AM
Aug-03-23 07:00AM
Jul-27-23 05:34PM
04:05PM
07:00AM
Jul-13-23 07:00AM
Jun-29-23 07:00AM
Jun-14-23 07:00AM
Jun-08-23 07:00AM
Jun-01-23 07:00AM
May-30-23 07:00AM
May-25-23 07:00AM
May-16-23 07:00AM
May-12-23 07:00AM
May-02-23 07:00AM
Apr-28-23 12:55PM
Apr-21-23 09:01AM
(Thomson Reuters StreetEvents) -13.98%
Apr-20-23 05:25PM
04:05PM
Apr-19-23 07:00AM
Apr-18-23 04:15PM
07:00AM
Apr-12-23 07:00AM
Mar-28-23 07:00AM
Mar-22-23 07:00AM
Feb-23-23 05:35PM
04:05PM
Feb-14-23 07:00AM
Feb-01-23 07:00AM
Jan-18-23 07:00AM
Jan-05-23 04:15PM
Nov-21-22 06:53AM
Nov-19-22 08:24AM
Nov-02-22 07:00AM
Oct-26-22 07:00AM
Oct-20-22 04:05PM
Oct-19-22 07:00AM
Oct-18-22 07:00AM
Oct-06-22 07:00AM
Oct-05-22 07:00AM
Oct-04-22 07:15AM
Sep-22-22 08:35AM
07:00AM
Sep-12-22 07:00AM
Sep-08-22 07:00AM
Sep-06-22 07:00AM
Aug-29-22 07:00AM
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Petersen Greg Director May 08 '24 Buy 2.04 12,255 25,000 36,421 May 10 07:30 AM HEDRICK MARC H Chief Executive Officer May 08 '24 Buy 2.04 12,255 25,000 12,425 May 10 07:30 AM Clowes Howard Director May 08 '24 Buy 2.04 9,804 20,000 21,497 May 10 07:30 AM Sims Andrew John Hugh MacIntyr Chief Financial Officer May 08 '24 Buy 2.04 4,902 10,000 5,717 May 10 07:30 AM Hawkins Richard J Director May 08 '24 Buy 2.04 4,902 10,000 4,903 May 10 07:30 AM Lenk Robert P Director May 08 '24 Buy 2.04 4,167 8,501 29,327 May 10 07:30 AM HEDRICK MARC H Chief Executive Officer Nov 20 '23 Sale 1.96 2,068 4,053 170 Dec 15 05:09 PM Lenk Robert P Director Nov 16 '23 Buy 1.95 1,000 1,950 25,160 Nov 17 07:00 AM Lenk Robert P Director Nov 15 '23 Buy 1.77 1,000 1,770 24,160 Nov 17 07:00 AM Lenk Robert P Director Nov 13 '23 Buy 1.43 4,000 5,720 23,160 Nov 15 07:00 AM Lenk Robert P Director Nov 10 '23 Buy 1.45 2,000 2,900 19,160 Nov 15 07:00 AM Lenk Robert P Director Nov 09 '23 Buy 1.59 4,199 6,676 17,160 Nov 13 07:00 AM Lenk Robert P Director Nov 08 '23 Buy 1.65 5,000 8,250 12,961 Nov 13 07:00 AM Lenk Robert P Director Nov 07 '23 Buy 1.64 6,000 9,840 7,961 Nov 08 07:00 AM Lenk Robert P Director Nov 06 '23 Buy 1.50 1,395 2,092 1,961 Nov 08 07:00 AM Clowes Howard Director Sep 13 '23 Buy 1.43 6,993 10,022 11,693 Sep 15 07:00 AM Petersen Greg Director Sep 11 '23 Buy 1.70 20,000 34,062 24,166 Sep 12 07:00 AM
Index -
P/E -
EPS (ttm) -4.59
Insider Own 36.09%
Shs Outstand 8.10M
Perf Week -3.63%
Market Cap 19.41M
Forward P/E -
EPS next Y -1.81
Insider Trans -0.09%
Shs Float 5.19M
Perf Month 6.70%
Income -37.13M
PEG -
EPS next Q -1.21
Inst Own 26.01%
Short Float 5.68%
Perf Quarter -11.48%
Sales 1.52M
P/S 12.77
EPS this Y 23.83%
Inst Trans 7.69%
Short Ratio 10.92
Perf Half Y -14.95%
Book/sh 2.15
P/B 1.11
EPS next Y 43.09%
ROA -80.89%
Short Interest 0.29M
Perf Year -33.98%
Cash/sh 2.85
P/C 0.84
EPS next 5Y 15.20%
ROE -106.15%
52W Range 2.01 - 4.55
Perf YTD -24.84%
Dividend Est. -
P/FCF -
EPS past 5Y 20.27%
ROI -156.90%
52W High -47.47%
Beta 0.73
Dividend TTM -
Quick Ratio 6.24
Sales past 5Y 106.75%
Gross Margin 97.57%
52W Low 18.91%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 6.24
EPS Y/Y TTM -24.35%
Oper. Margin -2586.30%
RSI (14) 44.20
Volatility 9.61% 8.34%
Employees 33
Debt/Eq 0.37
Sales Y/Y TTM -27.48%
Profit Margin -2434.69%
Recom 1.00
Target Price 22.50
Option/Short No / Yes
LT Debt/Eq 0.36
EPS Q/Q -44.50%
Payout -
Rel Volume 0.49
Prev Close 2.49
Sales Surprise -45.00%
EPS Surprise -13.56%
Sales Q/Q -76.12%
Earnings May 15 BMO
Avg Volume 26.99K
Price 2.39
SMA20 -2.29%
SMA50 -9.19%
SMA200 -21.18%
Trades
Volume 13,172
Change -4.02%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-11-21 Upgrade
Stifel
Hold → Buy
$4 → $24
Dec-03-20 Initiated
Cantor Fitzgerald
Buy
$32
Aug-26-20 Initiated
Piper Sandler
Overweight
$26
Aug-17-20 Resumed
ROTH Capital
Buy
$51
Aug-04-20 Initiated
H.C. Wainwright
Buy
$33
Jun-04-24 09:00AM
May-20-24 04:05PM
May-16-24 03:02AM
May-14-24 10:53PM
04:15PM
02:51PM
Loading…
May-09-24 02:51PM
Apr-18-24 04:05PM
Mar-20-24 08:00AM
Mar-08-24 02:06PM
Mar-07-24 09:54PM
04:01PM
Feb-26-24 09:00AM
Feb-05-24 04:05PM
Jan-04-24 04:05PM
Nov-21-23 04:15PM
04:05PM
Loading…
Nov-20-23 04:05PM
Nov-07-23 04:35PM
04:01PM
Sep-26-23 09:00AM
Sep-14-23 08:00AM
Sep-07-23 04:34PM
Aug-22-23 09:00AM
Aug-09-23 04:01PM
Jul-26-23 09:00AM
Jul-12-23 08:00AM
Jun-28-23 04:01PM
Jun-21-23 09:00AM
May-31-23 08:00AM
May-25-23 08:00AM
May-22-23 09:00AM
08:00AM
Loading…
May-08-23 08:00AM
May-03-23 04:05PM
Apr-27-23 09:00AM
Apr-19-23 09:00AM
Mar-09-23 04:05PM
Mar-05-23 02:00PM
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-15-23 04:05PM
Jan-03-23 09:00AM
Dec-12-22 07:30AM
Nov-29-22 04:05PM
Nov-22-22 04:05PM
Nov-14-22 06:10AM
06:00AM
Sep-26-22 04:05PM
Aug-31-22 09:00AM
Aug-16-22 07:30AM
Aug-09-22 04:01PM
Jul-27-22 04:05PM
Jul-24-22 08:27AM
Jul-20-22 08:32PM
May-16-22 04:05PM
May-10-22 04:01PM
May-06-22 10:25AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Apr-11-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 04:01PM
09:00AM
Feb-23-22 09:00AM
Feb-14-22 12:05PM
Jan-05-22 09:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-24-21 10:00AM
Nov-15-21 11:14AM
Nov-10-21 05:06PM
Nov-08-21 10:42AM
Nov-03-21 04:01PM
Oct-21-21 04:05PM
Sep-02-21 08:00AM
Aug-16-21 09:58AM
Aug-05-21 08:00AM
Aug-03-21 08:00AM
Aug-02-21 08:00AM
Jul-26-21 04:18PM
Jul-22-21 08:00AM
Jul-20-21 04:01PM
Jun-28-21 08:00AM
May-19-21 09:00AM
May-13-21 09:00AM
May-05-21 04:01PM
02:30PM
Apr-28-21 09:00AM
Apr-27-21 08:00AM
Apr-20-21 04:05PM
Apr-14-21 04:05PM
Mar-20-21 11:00AM
Mar-11-21 04:05PM
Mar-09-21 04:05PM
01:30PM
Mar-04-21 09:00AM
Mar-02-21 04:05PM
12:30PM
Feb-22-21 04:15PM
Feb-16-21 04:01PM
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McKew John C. Chief Scientific Officer Apr 03 '24 Sale 2.77 2,214 6,144 17,153 Apr 03 05:10 PM McKew John C. Chief Scientific Officer Feb 06 '24 Sale 3.03 438 1,328 18,403 Feb 07 05:22 PM McKew John C. Chief Scientific Officer Aug 02 '23 Sale 3.21 3,407 10,919 18,707 Aug 03 04:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite